Abstract
BACKGROUND: Acne vulgaris affects up to 80% of individuals aged 11 to 30 years and is one of the most common diseases in the world. Acne and its sequelae, such as redness, hyperpigmentation, irritation, and scarring, can have a deleterious effect on quality of life. Topical therapies are the standard of care, and compliance is central to success. AIMS: The purpose of the study was to evaluate the efficacy of a novel topical formulation (TASG) for the improvement of acne scar appearance and for reducing hyperpigmentation. PATIENTS/METHODS: This single-center, open-label clinical trial included healthy subjects (n = 27, age range 18 to 45 years) presenting with mild to moderate acne scarring and hyperpigmentation. Study duration was 4 visits over a 12-week period. Product was to be applied twice daily. RESULTS: No significant treatment-related adverse events were noted. Data show that 72.5% of subjects had smoother skin and reduced hyperpigmentation (as per observer grading of photographs) and redness at the final week 12 follow-up visit; subjective questionnaire results showed high patient satisfaction, with overall positive impressions of the product itself and its regular use. CONCLUSIONS: The data show that TASG is a safe and effective therapeutic option for improving the appearance of acne scars and related hyperpigmentation.